Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2002
Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marrocco-Trischitta Massimiliano M, Guerrini Paolo, Abeni Damiano, Stillo Francesco
Аннотация
BACKGROUND: Polidocanol sclerotherapy is a well-established therapeutic modality for the treatment of venous malformations. Systemic complications are extremely rare.
OBJECTIVE: To report a case of cardiac complication after polidocanol injection of peripheral venous malformation.
METHODS: A case report and a review of the English language literature using a published MEDLINE search strategy.
RESULTS: A patient undergoing polidocanol sclerotherapy for a symptomatic venous malformation of the right inferior limb developed cardiac arrest shortly after injection of the sclerosing agent which was promptly reversed.
CONCLUSION: Systemic complications following sclerotherapy may occur even when the sclerosant is injected in peripheral veins or venous malformations. Clinicians should be alerted to the possibility of uncommon but life-threatening adverse effects.
OBJECTIVE: To report a case of cardiac complication after polidocanol injection of peripheral venous malformation.
METHODS: A case report and a review of the English language literature using a published MEDLINE search strategy.
RESULTS: A patient undergoing polidocanol sclerotherapy for a symptomatic venous malformation of the right inferior limb developed cardiac arrest shortly after injection of the sclerosing agent which was promptly reversed.
CONCLUSION: Systemic complications following sclerotherapy may occur even when the sclerosant is injected in peripheral veins or venous malformations. Clinicians should be alerted to the possibility of uncommon but life-threatening adverse effects.